Abstract:Objective To study the association of NLR pyrin domain-containing protein 3 (NLRP3) inflammasome signaling pathway with the progression of chronic obstructive pulmonary disease (COPD).Methods Ninety four COPD patients,including 31 cases of stage Ⅱ (moderate),33 cases of stage Ⅲ (severe) and 30 cases of stage Ⅳ (extremely severe),were enrolled in the study.The pulmonary function was examined in patients both with stable and acute exacerbation stages.The expression of NLRP3,ASC,Casp-1,IL-1 β,IL-18 mRNA in peripheral blood mononuclear cells (PBMCs) were determined by real-time PCR.The concentrations of cytokines IL-1 β and IL-18 in serum were measured by ELISA.The correlation between the levels of NLRP3,ASC,Casp-1,IL-1β,IL-18 mRNA and pulmonary function was evaluated.Results Significantly higher levels of NLRP3,ASC,Casp-1,IL-1 β,IL-18 mRNA transcripts in PBMC from severe and extremely severe COPD groups were found both in the stable and acute exacerbation stage COPD patients,compared with moderate COPD group (all P＜0.05).And the above indexes in extremely severe COPD group were higher than those in severe COPD patients (all P＜0.05).Significantly higher levels of NLRP3,ASC,Casp-1,IL-1β,IL-18 mRNA transcripts in PBMC from acute exacerbation stage COPD patients were also found in moderate,severe and extremely Severe COPD groups compared with stable stages COPD group patients (all P＜ 0.05).Higher serum IL-1β and IL-18 levels in severe and extremely severe COPD groups were found both in the stable and acute exacerbation stage COPD patients compared with moderate COPD group (all P＜0.05).And the IL-1 β and IL-18 levels in extremely severe COPD group were higher than those in severe COPD group (both P＜0.05).Higher serum levels of IL-1 β and IL-18 levels from acute exacerbation stage COPD patients were also found in moderate,severe and extremely Severe COPD groups compared with stable stages COPD group patients (all P＜0.05).The increased levels of NLRP3,ASC,Casp-1,IL-1β,IL-18 mRNA transcripts in PBMC were negatively correlated with the values of FEV1,and FEV1/FVC in stable stages COPD group patients (all P＜0.01).Conclusion NLRP3 inflammasome activation is associated with the acute exacerbation and deterioration of pulmonary function and involved in the progression of COPD.

NLRP3 inflammasome activation in liver cirrhotic patients

Association of NLRP3 inflammasome signaling pathway with progression of chronic obstructive pulmonary disease

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

NLRP3 inflammasome in hepatic diseases: A pharmacological target

Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases

The Role of NLRP3 Inflammasome Activation Pathway of Hepatic Macrophages in Liver Ischemia–Reperfusion Injury

Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease

NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver disease

NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL‐17 and TNF in mice

NLRP3 Inflammasome in Acute and Chronic Liver Diseases

NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice

NLRP3 Inflammasome Activation Promotes Liver Inflammation and Fibrosis in Experimental Biliary Atresia.

Intestinal Microbiota and Innate Immunity-Related Gene Alteration in Cirrhotic Rats with Liver Transplantation

IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease

Interleukin-17A level in patients with liver cirrhosis and its clinical significances

Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis

NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate/S1P receptor 2/Gα(12/13)/MAPK signaling pathway

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease

Role of NLRP3 inflammasome in liver disease